Erratum to “Doubling Down on the PI3K-AKTmTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness” [Neoplasia 16 (2014) 43–72]

Eitemau Tebyg

• Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness
  gan: Pradip De, et al.
  Cyhoeddwyd: (2014-01-01)
• Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness
  gan: De, Pradip, et al.
  Cyhoeddwyd: (2014)
• Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): An oncoprotein with many hands
  gan: De, Pradip, et al.
  Cyhoeddwyd: (2014)
• Role of “oncogenic nexus” of CIP2A in breast oncogenesis: how does it work?
  gan: De, Pradip, et al.
  Cyhoeddwyd: (2015)
• PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
  gan: Ding, Liya, et al.
  Cyhoeddwyd: (2018)